News

Under the agreement Mr Velardi will continue the development on the selective depletion of allo-reactive T-cells from mismatched donors using Kiadis Pharma’s Atir. Kiadis Pharma is preparing for

The positive opinion from the Committee for Human Medicinal Products (CHMP), the committee responsible for the scientific assessment of new medicinal products, will be reviewed by the European

Sanofi-Aventis uses a range of Advanced Chemistry Development’s (ACD/Labs) analytical, predictive, and nomenclature tools such as ACD/SpecManager, ACD/Structure Design Suite, ACD/PhysChem Batch predictors, and ACD/Name. Additional support provided

According to the company, the product measurably improves radiologists’s reading times by employing the Dicom Digital Mammography standard. This standard enables the correct sequencing of scanned images on

The FDA has indicated that they cannot approve the NDA for ceftobiprole at this time. They have asked Johnson & Johnson Pharmaceutical R&D (J&JPRD) to conduct additional audit

Using the grant funding from the National Institutes of Health (NIH), EpiVax will develop a pro-inflammatory and non-tolerogenic HIV vaccine delivery system based on the dendritic cell targeting

Adverse events observed in this study were similar to those seen in prior studies of subcutaneous Relistor. The positive outcome reported was from the double-blind, randomized placebo-controlled portion

Treague is collaborating with Medicines for Malaria Venture, a Geneva-based not-for-profit organization dedicated to reducing malaria, to develop RS(+) mefloquine for the treatment of malaria in countries where

Net revenue for the third quarter of 2008 was $7.4 million, an increase of 3.5%, compared to $7.2 million for the third quarter of 2007. The increase in